Our subsequent molecular docking showed that each bioactive compounds (quercetin, wogonin, luteolin, naringenin, and kaempferol) of MGMD has favorable binding abilities with STAT3, PTGS2, JUN, VEGFA, EGFR, and ALOX5, further arguing the potential molecular mechanism of action of MGMD in asthma. This evidence concerns the gene JUN and asthma.